Midkine Promoter-Based Conditionally Replicative Adenovirus for Targeting Midkine-Expressing Human Bladder Cancer Model

Urology

Volumn 70, Issue 5, 2007, Pages 1009-1013

  Terao, Shuji ^a,b   Shirakawa, Toshiro ^c   Kubo, Shuji ^a   Bishunu, Acharya ^c   Lee, Sang Jin ^d   Goda, Kazumasa ^b   Tsukuda, Mamoru ^e   Hamada, Katsuyuki ^f   Tagawa, Masatoshi ^g   Takenaka, Atsushi ^b   Fujisawa, Masato ^b   Gotoh, Akinobu ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Faculty of Medicine   (Japan)

^c KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d INDIANA UNIVERSITY   (United States)

^e YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^f EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g CHIBA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS MIDKINE E1A PROTEIN; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CONDITIONALLY REPLICATING ADENOVIRUS; LUCIFERASE; MESSENGER RNA; MIDKINE; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CELL GROWTH; CELL LINE; CELL TYPE; CONTROLLED STUDY; CYTOMEGALOVIRUS; EMBRYO; GROWTH INHIBITION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; FEASIBILITY STUDIES; GENE THERAPY; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; NERVE GROWTH FACTORS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; VIRUS REPLICATION;

EID: 36549069246     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.07.003     Document Type: Article

References (24)

1. Hemminki A. From molecular changes to customised therapy. Eur J Cancer 38 (2002) 333-338
2. Bauerschmitz G.J., Barker S.D., and Hemminki A. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents. Int J Oncol 21 (2002) 1161-1174
3. Kanerva A., and Hemminki A. Modified adenoviruses for cancer gene therapy. Int J Cancer 110 (2004) 475-480
4. Ganly I., Kirn D., Eckhardt G., et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 6 (2000) 798-806
5. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?. Gene Ther 8 (2001) 89-98
6. Biederer C., Ries S., Brandts C.H., et al. Replication-selective viruses for cancer therapy. J Mol Med 80 (2002) 163-175
7. Ring C.J. Cytolytic viruses as potential anti-cancer agents. J Gen Virol 83 (2002) 491-502
8. Heise C., and Kirn D.H. Replication-selective adenoviruses as oncolytic agents. J Clin Invest 105 (2000) 847-851
9. Alemany R., Balague C., and Curiel D.T. Replicative adenoviruses for cancer therapy. Nat Biotechnol 18 (2000) 723-727
10. Tomomura M., Kadomatsu K., Nakamoto M., et al. A retinoic acid responsive gene, MK, produces a secreted protein with heparin binding activity. Biochem Biophys Res Commun 171 (1990) 603-609
11. Kadomatsu K., Huang R.P., Suganuma T., et al. A retinoic acid responsive gene MK found in the teratocarcinoma system is expressed in spatially and temporally controlled manner during mouse embryogenesis. J Cell Biol 110 (1990) 607-616
12. O'Brien T., Cranston D., Fuggle S., et al. The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res 56 (1996) 2515-2518
13. Curiel D.T. The development of conditionally replicative adenoviruses for cancer therapy. Clin Cancer Res 6 (2000) 3395-3399
14. Rodriguez R., Schuur E.R., Lim H.Y., et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 57 (1997) 2559-2563
15. Yajima T., Yagihashi A., Kameshima H., et al. Quantitative reverse transcription-PCR assay of the RNA component of human telomerase using the TaqMan fluorogenic detection system. Clin Chem 44 (1998) 2441-2445
16. Hamada K., Sakaue M., Alemany R., et al. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells. Gynecol Oncol 63 (1996) 219-227
17. Hamada K., Kohno S., Iwamoto M., et al. Identification of human IAI.3B promoter element and its use in the construction of a replication-selective adenovirus for ovarian cancer therapy. Cancer Res 63 (2003) 2506-2512
18. Gleave M., Hsieh J.T., Gao C.A., et al. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 51 (1991) 3753-3761
19. Connor J., Bannerji R., Saito S., et al. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med 177 (1993) 1127-1134
20. Sutton M.A., Berkman S.A., Chen S.H., et al. Adenovirus-mediated suicide gene therapy for experimental bladder cancer. Urology 49 (1997) 173-180
21. Wildner O. Comparison of replication-selective, oncolytic viruses for the treatment of human cancers. Curr Opin Mol Ther 5 (2003) 351-361
22. Li Y., Pong R.C., Bergelson J.M., et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 59 (1999) 325-330
23. Shirakawa T., Hamada K., Zhang Z., et al. A COX-2 promoter-based replication-selective adenoviral vector to target the COX-2-expressing human bladder cancer cells. Clin Cancer Res 10 (2004) 4342-4348
24. Okegawa T., Nutahara K., Pong R.C., et al. Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor. J Urol 174 (2005) 747-752